Disease Markers / 2018 / Article / Tab 2

Review Article

Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients

Table 2

Summary of the meta-analysis results.

AnalysisUnivariate analysisMultivariate analysis
NHR (95% CI)pI2PhNHR (95% CI)pI2Ph

CA15-3 DFS
 All142.61 (2.17–3.13)<0.001500.02101.56 (1.38–1.76)<0.001310.16
 Subgroup 1
  Primary early-stage breast cancer92.57 (2.14–3.08)<0.001210.2571.80 (1.53–2.11)<0.00100.63
  Metastatic breast cancer22.00 (1.46–2.74)<0.00100.6911.28 (0.43–3.80)0.65
  Primary all-stage or unclear-stage breast cancer32.88 (1.54–5.41)<0.001820.00421.28 (1.06–1.55)<0.001400.20
 Subgroup 2
  Cut-off ≤ 2562.84 (2.30–3.50)<0.00100.7751.80 (1.50–2.16)<0.00100.85
  Cut-off > 2562.69 (1.87–3.87)<0.001750.00141.39 (1.17–1.64)<0.001590.06
 Subgroup 3
  Asia and Africa83.18 (2.46–4.11)<0.001440.0861.96 (1.57–2.44)<0.00100.65
  Europe and America62.14 (1.82–2.52)<0.00100.6741.41 (1.22–1.63)<0.001240.27
 Subgroup 4
  Sample size < 500112.37 (2.00–2.81)<0.001200.2671.78 (1.50–2.10)<0.00100.65
  Sample size ≥ 50033.36 (2.01–5.61)<0.001790.00831.35 (1.13–1.61)0.001500.14
 Subgroup 5
  Publish year > 201072.82 (2.3–3.48)<0.00100.4561.80 (1.50–2.17)<0.00100.53
  Publish year ≤ 201072.45 (1.86–3.23)<0.001690.00441.39 (1.19–1.64)<0.001390.18
CA15-3 OS
 All212.86 (2.31–3.54)<0.00172<0.0001152.03 (1.76–2.33)<0.00100.45
 Subgroup 1
  Primary early-stage breast cancer72.95 (2.28–3.82)<0.001220.2661.93 (1.46–2.55)<0.00100.84
  Metastatic breast cancer61.79 (1.51–2.12)<0.00100.6631.85 (1.47–2.32)<0.00100.78
 Primary all-stage or unclear-stage breast cancer83.87 (2.74–5.46)<0.00174<0.000162.31 (1.83–2.93)<0.001470.09
 Subgroup 2
  Cut-off ≤ 2553.11 (2.39–4.05)<0.00100.5951.98 (1.46–2.69)<0.00100.90
  Cut-off > 25103.57 (2.62–4.88)<0.00174<0.000172.24 (1.79–2.80)<0.001460.09
 Subgroup 3
  Asia and Africa113.50 (2.59–4.71)<0.001700.000281.93 (1.58–2.35)<0.001340.16
  Europe and America102.35 (1.74–3.18)<0.001720.000272.13 (1.74–2.60)<0.00100.81
 Subgroup 4
  Sample size < 500182.87 (2.24–3.7)<0.00175<0.0001122.03 (1.74–2.38)<0.001210.23
  Sample size ≥ 50032.72 (1.96–3.78)<0.001370.2031.99 (1.43–2.77)<0.00100.99
 Subgroup 5
  Publish year > 2010103.17 (2.33–4.31)<0.001620.00581.82 (1.52–2.18)<0.00100.90
  Publish year ≤ 2010112.65 (1.94–3.62)<0.00179<0.000172.41 (1.92–3.03)<0.001210.27
CEA DFS
 All102.60 (2.23–3.04)<0.00100.9191.77 (1.53–2.04)<0.00100.82
 Subgroup 1
  Primary early-stage breast cancer62.80 (2.24–3.52)<0.00100.4851.94 (1.56–2.40)<0.00100.72
  Metastatic breast cancer12.31 (1.26–4.24)0.00721.91 (1.22–3.00)0.00500.71
  Primary all-stage or unclear-stage breast cancer32.45 (1.94–3.09)<0.00100.8021.58 (1.28–1.96)<0.00100.56
 Subgroup 2
  Cut-off ≤ 562.77 (2.29–3.37)<0.00100.4861.74 (1.49–2.04)<0.00100.54
  Cut-off > 532.31 (1.72–3.10)<0.00100.9811.84 (1.07–3.16)<0.001
 Subgroup 3
  Asia and Africa62.65 (2.19–3.20)<0.00100.4651.95 (1.53–2.48)<0.00100.89
  Europe and America42.50 (1.89–3.32)<0.00100.8041.67 (1.40–2.00)<0.00100.52
 Subgroup 4
  Sample size < 50062.62 (2.11–3.24)<0.00100.5471.87 (1.54–2.26)<0.00100.97
  Sample size ≥ 50042.59 (2.06–3.25)<0.00100.6421.65 (1.33–2.05)<0.001590.12
 Subgroup 5
  Publish year > 201052.79 (2.15–3.60)<0.00100.5071.87 (1.54–2.26)<0.00100.97
  Publish year ≤ 201052.50 (2.05–3.04)<0.00100.7421.65 (1.33–2.05)<0.001590.12
CEA OS
 All162.46 (1.93–3.15)<0.00170<0.000181.72 (1.49–1.99)<0.00100.69
 Subgroup 1
  Primary early-stage breast cancer73.68 (2.65–5.09)<0.001330.1741.95 (1.49–2.57)<0.00100.89
  Metastatic breast cancer41.52 (1.27–1.82)<0.00100.4111.37 (1.02–1.85)0.04
  Primary all-stage or unclear-stage breast cancer52.61 (1.88–3.62)<0.001420.1431.79 (1.46–2.20)<0.00100.64
 Subgroup 2
  Cut-off ≤ 583.80 (2.67–5.39)<0.001590.0261.86 (1.56–2.20)<0.00100.88
  Cut-off > 542.34 (1.73–3.17)<0.00100.9611.77 (1.03–3.03)<0.001
 Subgroup 3
  Asia and Africa112.82 (2.07–3.85)<0.00172<0.00171.65 (1.38–1.96)<0.00100.70
  Europe and America51.87 (1.26–2.77)0.002610.0411.91 (1.48–2.46)<0.001
 Subgroup 4
  Sample size < 500132.48 (1.84–3.34)<0.00175<0.000161.64 (1.37–1.95)<0.00100.60
  Sample size ≥ 50032.29 (1.75–3.00)<0.00100.4821.91 (1.50–2.45)<0.00100.96
 Subgroup 5
  Publish year > 201093.27 (2.22–4.82)<0.00173<0.000161.64 (1.37–1.95)<0.00100.60
  Publish year ≤ 201071.82 (1.39–2.39)<0.001530.0521.91 (1.50–2.45)<0.00100.96

N: number of studies; HR: hazard ratio; 95% CI: 95% confidence interval; Ph: values of Q test for heterogeneity test; OS: overall survival; DFS: disease-free survival; “—” means unavailable.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.